Panostaja Group Annual Report and Report on the Management and Control System 2022 published
Panostaja Oyj Annual Financial Report 17th January 2023, 13.00 p.m.
Panostaja Group Annual Reportand Report on the Management and Control System 2022published
Panostaja Group´s Annual Report 2022 with Financial Statements for the financial year November 1, 2021-October 31, 2022 has been published today.
Link to the Annual Report: https://vuosikertomus.panostaja.fi/en/annual-report-2022/
Panostaja publishes the financial statements as an xHTML file in accordance with the European Single Electronic Format (ESEF) reporting requirements. The main statements of the consolidated financial statements are marked with XBRL marks. The XBRL report is not verified.
Additionally, Panostaja Group´s Remuneration Report and The Report on the Management and Control System for the financial year November 1, 2021-October 31, 2022 have been published today.
The financial statement is attached to this release as both an xHTML file and a PDF file. The Remuneration Report and the Corporate Governance Statement are attached as separate PDF attachments. The Reports can also be read at www.panostaja.fi/en.
Panostaja Oyj
Tapio Tommila
CEO
Further information:
CEO Tapio Tommila +358 40 527 6311
Panostaja is an investment company developing Finnish companies in the growing service and software sectors as an active shareholder.The company aims to be the most sought-after partner for business owners selling their companies as well as for the best managers and investors. Together with its partners, Panostaja increases the Group's shareholder value and creates Finnish success stories. Panostaja has a majority holding in four investment targets. Panostaja’s shares (PNA1V) are quoted on the Nasdaq Helsinki Stock Exchange. In the 2022 financial year, the Group’s net sales totaled MEUR 137,9.
Attachments
- Panostaja Oyj Financial Statements 2022
- Panostaja Oyj Management and Control System 2022
- Panostaja Oy Remuneration Report 2022
- Panostaja Oyj-2022-10-31
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release
Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern
ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release
SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release
If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and
Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342